Literature DB >> 1387151

Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat.

J Hill1, T F Lindsay, F Ortiz, C G Yeh, H B Hechtman, F D Moore.   

Abstract

We examined the role of C activation in ischemia reperfusion injury by inhibiting C activation in a rat model of mesenteric arterial occlusion. In anesthetized rats, 60 min of mesenteric arterial occlusion was followed by 3 h of reperfusion. PBS alone or containing soluble C receptor 1 (3 or 6 mg) was administered i.v. Controls underwent laparotomy without ischemia. Relative serum C activities were assessed by hemolytic assay, neutrophil (polymorphonuclear leukocyte) sequestration by tissue content of myeloperoxidase (MPO) activity, intestinal mucosal injury by histologic grading, lung vascular permeability by the ratio of bronchoalveolar lavage to blood concentration of radiolabeled BSA, and endothelial cell injury was quantified by measurement of plasma factor VIII-related Ag. After reperfusion, PBS-treated animals had increased intestinal MPO (0.048 +/- 0.007 U/g) compared to sham (0.022 +/- 0.005 U/g (p less than 0.05)) and intestinal mucosal injury score (2.490 +/- 0.221) compared to sham (0.331 +/- 0.045 (p less than 0.05)). Treatment with 6 mg soluble C receptor 1 15 min before reperfusion reduced intestinal MPO (0.017 +/- 0.003 U/g (p less than 0.05)) and mucosal injury (1.733 +/- 0.168 (p less than 0.05)) compared to PBS control. PBS-treated animals also demonstrated increased lung MPO (0.314 +/- 0.025 U/g vs 0.085 +/- 0.018 in sham (p less than 0.05)) and increased lung permeability (bronchoalveolar lavage/blood cpm 11.32 +/- 1.35 x 10(-3) vs sham 2.22 +/- 0.19 x 10(-3) (p less than 0.05)). Treatment with 6 mg soluble C receptor 1 15 min before reperfusion or at reperfusion reduced the lung permeability (bronchoalveolar lavage/blood cpm 3.90 +/- 0.79 x 10(-3) and 5.08 +/- 0.75, respectively (both p less than 0.05)) compared to PBS control, but did not reduce lung MPO (0.342 +/- 0.031 U/g and 0.246 +/- 0.025), respectively. Treatment with sCR1 also reduced the release of factor VIII-related Ag, 5-day mortality, and C hemolytic activity. In this model, C is a major mediator of intestinal injury and extraintestinal injury.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387151

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Complement activation promotes muscle inflammation during modified muscle use.

Authors:  J Frenette; B Cai; J G Tidball
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Mediators of ischemia-reperfusion injury of rat lung.

Authors:  M J Eppinger; G M Deeb; S F Bolling; P A Ward
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris.

Authors:  R J Quigg; C He; B K Hack; J J Alexander; B P Morgan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 4.  Complement in ischemia reperfusion injury.

Authors:  Niels C Riedemann; Peter A Ward
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

5.  Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury.

Authors:  Ming Zhang; William G Austen; Isaac Chiu; Elisabeth M Alicot; Rachel Hung; Minghe Ma; Nicola Verna; Min Xu; Herbert B Hechtman; Francis D Moore; Michael C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-03       Impact factor: 11.205

6.  A novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues.

Authors:  Ledia Goga; Sathnur B Pushpakumar; Gustavo Perez-Abadia; Paul Olson; Gary Anderson; Chirag V Soni; John H Barker; Claudio Maldonado
Journal:  J Surg Res       Date:  2010-10-16       Impact factor: 2.192

7.  CR2+ marginal zone B cell production of pathogenic natural antibodies is C3 independent.

Authors:  Keith M Woods; Michael R Pope; Sara M Hoffman; Sherry D Fleming
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

8.  Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic.

Authors:  Deborah A Fraser; Claire L Harris; Richard A G Smith; B Paul Morgan
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

Review 9.  Membrane lipid interactions in intestinal ischemia/reperfusion-induced Injury.

Authors:  Emily Archer Slone; Sherry D Fleming
Journal:  Clin Immunol       Date:  2014-05-09       Impact factor: 3.969

10.  Intestinal lipid alterations occur prior to antibody-induced prostaglandin E2 production in a mouse model of ischemia/reperfusion.

Authors:  Byron L Sparkes; Emily E Archer Slone; Mary Roth; Ruth Welti; Sherry D Fleming
Journal:  Biochim Biophys Acta       Date:  2010-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.